Here is my final consolidated review.

---

## Summary

This paper introduces the problem of PPI candidate ranking — using known interaction partners of a target protein to rank novel candidate partners — and proposes a two-stage framework. In the first stage, predicted contact maps from D-SCRIPT/Topsy-Turvy are used to identify "active residue regions" on known partners, and cosine similarity over those regions is used to rank candidates. In the second stage, the top-10 candidates are re-ranked using biochemical, structural, and semantic signals. The method is evaluated prospectively on novel interactions appearing in STRING v12 but absent from v11.

## Strengths

- **Prospective evaluation design (Section 5.1).** The paper evaluates on novel interactions that appear in STRING v12 but were absent from v11, simulating a genuine forward-prediction scenario. This is a meaningful departure from standard retrospective PPI benchmarks that split a single database snapshot, and it addresses a real gap in the PPI evaluation literature — whether models can anticipate interactions that will only be experimentally confirmed later. This design choice is itself a methodological contribution the field could adopt more broadly. [impact=+9.32]

- **Scoping of a meaningful new problem.** The paper clearly identifies that standard PPI binary classification is not well-suited for the practical task of prioritizing candidates for experimental validation, and formulates PPI candidate ranking as a distinct problem. The problem framing is well-motivated and practically relevant. [impact=+9.15]

- **Methodological insight in interpretability-guided retrieval (Section 4.1).** Using predicted contact maps to select active residue regions, then computing similarity only over those sub-sequences, exploits the internal structure of D-SCRIPT/Topsy-Turvy in a biologically motivated way. The intuition that novel partners are most likely to resemble known partners at the binding-interface level is well-founded and makes the method more than a black-box ranking approach. [impact=+2.28]

- **Comprehensive re-ranking analysis (Table 2).** Testing ten different re-ranking signals and comparing them pairwise is thorough. The finding that PubMedBERT gives the most consistent improvements while lightweight annotation heuristics (TF-IDF, token overlap) are surprisingly competitive is informative for future work. [impact=+2.10]

## Weaknesses

### Fatal

None. The paper's core flaws are fixable with additional experiments and corrections.

### Major

- **Overstated headline claim (lines 25, 278–279).** The abstract and conclusion state that the method "improve[s] ranking metrics by two orders of magnitude" (~100×). Table 1 does not support this. The largest gain is Recall@5 (0.0071→0.1832, ~26×, roughly 1.4 orders). MRR improves only ~5×. The maximum ratio across any metric in Table 1 is about 25–26×, which is one order of magnitude, not two. This claim is materially misleading and should be corrected to specific, verifiable improvement ratios. [impact=-10.00]

- **Missing ablation to isolate the active-residue contribution (Section 4.1 vs. baselines in Table 1).** The proposed method uses known partners KP(p) as anchors, giving it access to information (the set of confirmed interactors for protein *p*) that the baselines (raw D-SCRIPT, Topsy-Turvy, xCAPT5) do not have. The paper compares "using known partners + active residues" against "not using known partners at all." A critical missing ablation is: rank candidates by max cosine similarity to known partners using the *full* embedding (no active-residue selection). Without this, the improvement cannot be attributed to the interpretability-guided active-residue mechanism — it may simply come from having access to known partner information. This undermines the paper's core attribution claim. [impact=-9.96]

- **Incomplete re-ranking evaluation (Section 4.2, Table 2).** Re-ranking operates only on the top-10 candidates from the initial retrieval (Section 4.2, line 109). Since Success@10 for the D-SCRIPT-based method is only 12.77% (Table 1), ~87% of target proteins have no true novel partner in the candidates subjected to re-ranking. The re-ranking analysis reports only pairwise rank-shift percentages (Table 2) — "fraction maintained or improved" — without reporting any end-to-end retrieval metric after re-ranking (Recall@k, Success@k, MRR for the combined pipeline). This makes it impossible to assess the practical value of the full framework. [impact=-10.00]

### Minor

- **No uncertainty quantification.** All metrics in Table 1 are single-point estimates without standard deviations, confidence intervals, or significance tests. Given the large candidate space, ranking metrics could be sensitive to random variation. [impact=-0.48]

- **The xCAPT5 baseline is under-documented.** It is unclear whether xCAPT5 was retrained on the same STRING v11 data as the proposed method or used with pretrained weights. Differences in training data could confound the comparison. [impact=-0.00]

- **No sensitivity analysis of contact-map quality.** The active-region selection depends entirely on predicted D-SCRIPT/Topsy-Turvy contact maps *C(p, p_k)*, which could be noisy or inaccurate. The paper does not analyze how errors in contact maps propagate to ranking quality (e.g., via a random-residue baseline or using full embeddings without selection). [impact=-0.00]

- **STRING v12 test set composition.** The "new" interactions in v12 (experimental support > 0) may conflate database curation lag with genuine novel discovery — interactions may have been predictable from non-experimental evidence already present in v11 (co-expression, text mining). The paper does not characterize what fraction of v12's new interactions represent genuinely novel biology. [impact=-0.10]

- **Computational cost is acknowledged but not discussed as a limitation.** The paper states "runtimes in the order of hundreds of hours" (line 233). The Limitations section (Section 6) discusses the known-partner assumption and the interpretability framing but does not address the practical feasibility bottleneck, which undermines the stated motivation of enabling experimental prioritization. [impact=-4.77]

### Trivial

None.

## Nice-to-Haves

- Stratify results by number of known partners, sequence length, or functional class to provide practical guidance for when the method is most applicable and when to fall back to raw scores.
- Consider including additional lightweight baselines that also use known partner information (e.g., max full-embedding similarity), as discussed in the Major weaknesses.

## Removed Points

These points were flagged for removal from the harsh critic's review. Treat them with caution:

- **"Unfair comparison" framing.** The reviewer described the comparison as "fundamentally unfair" because the proposed method uses privileged information (known partners). However, this is the method's design — the paper is proposing a method that explicitly uses known partners. This is not a fairness issue but a missing ablation issue. The weakness was reframed and kept as a Major weakness (missing ablation) above.

- **Related work missing ranking literature.** The paper is not required to cover ranking methods from other domains. Scope creep — removed.

- **pDockQ underperformance analysis.** This is the paper's own observation and analysis, not a weakness. Removed.

- **Interpretability tension.** The paper explicitly acknowledges in the Limitations (lines 289–294) that it does not use interpretability for explanation generation. Removed as already addressed.

- **Formatting/typographical nitpicks.** Parser artifacts, not author errors. Removed.

- **"Method's computational cost is prohibitive" framed as fatal.** The cost is a genuine concern but acknowledged in the paper; reframed as a Minor weakness above.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Correct the headline claim.** Replace "two orders of magnitude" with precise improvement ratios (e.g., "up to 26× at Recall@5") and clearly identify which metric supports the claim. Show the full distribution rather than cherry-picking the most favorable ratio.

2. **Add the critical ablation.** Run a baseline that ranks candidates by max cosine similarity to any known partner using the *full* embedding (no active-residue selection). Report how much of the gain remains. This is essential to attribute the improvement to the interpretability-guided mechanism.

3. **Complete the re-ranking evaluation.** Report end-to-end retrieval metrics (Recall@k, Success@k, MRR) for the combined retrieval + re-ranking pipeline. Show how many targets are excluded by the top-10 cutoff and discuss the trade-off with computational cost for larger cutoffs (e.g., top-50).

4. **Discuss computational cost in the Limitations section.** State what fraction of the human proteome is practically accessible under a realistic computational budget and what mitigations could be considered.

---

## Score and Decision

**Calibration anchor summary:**

| Filepath | Avg Score | Round | Itemized | Comparison |
|---|---|---|---|---|
| jsQPjIaNNh.md (Illuminating Protein Function) | 5.25 | 1 | Yes | Similar evaluation issues (missing baselines, ablation gaps), comparable weakness severity; my paper has a stronger prospective evaluation design. |
| eh1fL0zw8o.md (LLaPA for PPI) | 6.00 | 1 | Yes | Stronger SOTA results but similar unfair-comparison concern; my paper has weaker experimental support. |
| itGkF993gz.md (MAPE-PPI) | 5.67 | 1 | Yes | Stronger experiments and efficiency claims; accepted despite missing references issue. |
| wCwz1F8qY8.md (DeepSSInter) | 5.00 | 1 | Yes | Incremental contribution claim; my paper has better novelty but comparable evaluation gaps. |
| ZkpDdCQUC4.md (NovoBench-100K) | 4.60 | 2 | Yes | Dataset paper with insufficient technical ML contribution; my paper has stronger methodology. |
| 44IKUSdbUD.md | 3.00 | 1 | No | Much weaker methodologically. |
| nWO75tVjfp.md | 3.00 | 1 | No | Much weaker. |
| S2WHlhvFGg.md | 3.00 | 1 | No | Much weaker. |
| yF19SY1i8M.md | 6.00 | 2 | No | NLP evaluation paper, different domain but similar structural evaluation issues. |
| 4o4fDJL6I7.md | 4.00 | 2 | No | NAS ranking loss evaluation. |

**Round 1 bracket:** 3.5–5.5. Above weak papers (2.5–3.0) but below structurally sound papers (5.6+).

**Narrowing:** Compared against the closest anchors (Illuminating Protein Function at 5.25, NovoBench-100K at 4.60, DeepSSInter at 5.00). My paper shares the same pattern: interesting core idea + novel problem framing, but evaluation issues severe enough to prevent acceptance. The missing ablation is the most consequential weakness — without it, the paper cannot support its central attribution claim that the active-residue mechanism drives improvement. The overstated headline claim further erodes credibility. These issues are fixable, giving the paper a clear path to a stronger version, but in its current form the evidence does not support the conclusions drawn.

**Final score: 4.5** — borderline reject. The paper has a well-motivated problem and a clever core idea, but the evaluation has three significant issues that together prevent acceptance: the headline claim is factually wrong, the core mechanism is unisolated from a confound, and the re-ranking analysis is structurally incomplete. These are fixable with additional experiments and corrections, but the current submission does not provide sufficient evidence for its claims.

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>